title: Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis.
abstract: OBJECTIVE
  The association between piperacillin/tazobactam and the positivity of the galactomannan (GM) detection ELISA test is well described. Little information is available about the kinetics of GM in patients treated with piperacillin/tazobactam. The present study aimed at clarifying the baseline interaction between piperacillin/tazobactam and GM in patients receiving this drug.
  
  
  METHODS
  Seven patients undergoing abdominal surgery received perioperative prophylaxis with piperacillin/tazobactam. Each patient received three doses of 4.5 g of the drug, administered at 8 h intervals (one before and two after surgery). Three patients received antibiotic batches with 'medium' (GM-index = 1.782) and four patients received antibiotic batches with 'high' (GM-index = 6.665) GM content. Serum samples for GM evaluation were collected before drug infusion and at times +1, +3, +6 and +8 h after the first and third infusions.
  
  
  RESULTS
  GM levels increased after infusion, in particular when batches with 'high' GM content were used. Moreover, a non-statistically significant increase between the first dose and the third dose was observed. All samples taken >6 h after administration were negative (GM-index < 0.2), both with the 'medium' and the 'high' GM content batches.
  
  
  CONCLUSIONS
  The low content of GM 8 h after piperacillin/tazobactam infusion suggests that in non-neutropenic cancer patients with solid tumours receiving up to three doses of piperacillin/tazobactam, serum sampling for GM detection should be performed immediately before the next piperacillin/tazobactam administration.
authors.affiliation: Advanced Biotechnology Center, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Machetti
authors.forename: M J
authors.initials: MJ
authors.lastname: Majabo
authors.forename: E
authors.initials: E
authors.lastname: Furfaro
authors.forename: N
authors.initials: N
authors.lastname: Solari
authors.forename: A
authors.initials: A
authors.lastname: Novelli
authors.forename: F
authors.initials: F
authors.lastname: Cafiero
authors.forename: C
authors.initials: C
authors.lastname: Viscoli
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D001424:Bacterial Infections / Q000517:prevention & control*; D003106:Colon / Q000601:surgery; D005189:False Positive Reactions; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D005743:Gastrectomy / Q000009:adverse effects*; D006801:Humans; D007700:Kinetics; D008297:Male; D008351:Mannans / Q000097:blood*; D008875:Middle Aged; D010397:Penicillanic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D010878:Piperacillin / Q000009:adverse effects / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D012007:Rectum / Q000601:surgery
chemical_list: D000900:Anti-Bacterial Agents; D008351:Mannans; C012990:galactomannan; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin; D005690:Galactose